Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 10,564 matching trials from the live ClinicalTrials.gov search.

Filters: Cincinnati, Ohio Clear all

Conditions: Neoplasms, Breast
Interventions: Lapatinib/nab-Paclitaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 13
States / cities: La Verne, California • Long Beach, California • Fort Myers, Florida + 10 more

Conditions: Obesity
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 15 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Small Cell Lung Cancer
Interventions: Ifinatamab deruxtecan, Topotecan, Amrubicin, Lurbinectedin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 30
States / cities: Springdale, Arkansas • Fullerton, California • Los Angeles, California + 24 more

Conditions: Obstructive Sleep Apnea
Interventions: Inspire Upper Airway Stimulation System; Device
Lead sponsor: Inspire Medical Systems, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 929 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 15
States / cities: Palo Alto, California • St. Petersburg, Florida • Tampa, Florida + 12 more

Conditions: Hypertrophic Cardiomyopathy
Interventions: TN-201; Genetic
Lead sponsor: Tenaya Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 10
States / cities: La Jolla, California • San Francisco, California • Atlanta, Georgia + 7 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Idelalisib, Bendamustine, Rituximab, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Fullerton, California • La Jolla, California • Santa Maria, California + 20 more

Conditions: Asthma
Interventions: Omalizumab, Inhaled Corticosteroid Boost Therapy (ICS), Placebo omalizumab, Placebo fluticasone; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years to 17 Years
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Denver, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 5 more

Conditions: Chronic Pain, Osteoarthritis of the Knee
Interventions: Buprenorphine, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 40 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 87
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more

Conditions: Metastatic Melanoma
Interventions: Allovectin-7®, Dacarbazine (DTIC), Temozolomide (TMZ); Biological · Drug
Lead sponsor: Vical; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 27
States / cities: Tucson, Arizona • Little Rock, Arkansas • Bakersfield, California + 21 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, 25 mg PF-04991532, 75 mg PF-04991532, 150 mg PF-04991532, 300 mg PF-04991532, Sitagliptin 100 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 25
States / cities: Little Rock, Arkansas • Roseville, California • Denver, Colorado + 22 more

Conditions: Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder
Interventions: Booster Treatment, No-Booster, No intervention, Treatment As Usual; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Years to 11 Years
Enrollment: 254 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 2
States / cities: Cincinnati, Ohio • Pittsburgh, Pennsylvania

Conditions: Back Pain Lower Back Chronic
Interventions: Placebo, Hydrocodone bitartrate; Drug
Lead sponsor: Zogenix, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 51
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Anaheim, California + 47 more

Conditions: Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 23 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Leukemia
Interventions: asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, pegaspargase, prednisone, therapeutic hydrocortisone, thioguanine, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy; Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 9 Years
Enrollment: 1,970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2007
U.S. locations: 31
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 24 more

Conditions: Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
Interventions: ATX-101, Placebo; Drug
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 65 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Bradenton, Florida + 3 more

Conditions: Appendix Rupture, Pain, Pain, Postoperative
Interventions: VR-Biofeedback, VR-Distraction; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 8 Years to 18 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetic Gastroparesis
Interventions: CIN-102 Dose 15mg or 10mg, Placebo; Drug
Lead sponsor: CinDome Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 100
States / cities: Dothan, Alabama • Foley, Alabama • Huntsville, Alabama + 82 more

Conditions: Patients Undergoing Repeat Peripheral Artery Revascularization
Interventions: CV-18C3, Standard of Care; Drug · Procedure
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Sacramento, California • Atlantis, Florida • Jacksonville, Florida + 4 more

Conditions: Rett Syndrome, RTT
Interventions: GWP42003-P, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: CPI-RSV-F Vaccine (BLB-201); Biological
Lead sponsor: Blue Lake Biotechnology Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Cincinnati, Ohio • North Charleston, South Carolina

Conditions: HIV-associated Enteropathy
Interventions: Serum-derived bovine immunoglobulin protein isolate (SBI), Placebo; Other
Lead sponsor: Entera Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 7 more

Conditions: Colorectal Neoplasms
Interventions: GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Fluoropyrimidine plus leucovorin, Bevacizumab; Drug
Lead sponsor: Seattle Project Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 43
States / cities: Gilbert, Arizona • Springdale, Arkansas • Los Angeles, California + 36 more

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Enterocolitis, Necrotizing, Intestinal Perforation
Interventions: Laparotomy, Drainage; Procedure
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 8 Weeks
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 18 more

Conditions: Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions: NG101, Placebo; Drug
Lead sponsor: Neurogastrx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 83
States / cities: Dothan, Alabama • Foley, Alabama • Mobile, Alabama + 69 more

Search by objective public record fields.

Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC

Adolescent Gastric By-pass and Diabetic Precursors

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations

Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee

A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

Resources to Enhance the Adjustment of Children (REACH)

Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain

MRI Based Biomarkers in Pediatric Autoimmune Liver Disease

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

Virtual Reality for Appendectomy Pain

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.

Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults

Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis